STUDboardsPlay · Research · Self · Fit · Money · Learn · Study · Plan · Token STUDtokenOptional

STUDresearch · Peptide

Semax

Also known as

Met-Glu-His-Phe-Pro-Gly-Pro · MEHFPGP · H-MEHFPGP-OH · ACTH(4-7)-PGP · (Pro8,Gly9,Pro10)ACTH-(4-10) · ACTH(4-10) analog (heptapeptide shorthand) · Semax 0.1% · Semax 1% · Semax-Hept (1% product talk) · SEMAX® (Russian pharmacy brand discussions) · Семакс · N-Acetyl Semax (related analog — not identical) · N-Acetyl Semax Amidate / NASA (related analog — not identical) · CAS 80714-61-0 (primary registry discussions) · MW ~813.93 g/mol (C37H51N9O10S)

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗
Peptide Lots of talk Systemic Nasal Cognitive / nootropic peptides

Brain-first — intranasal is the main clinical and community route. Subcutaneous use is a separate minority practice; oral use is not mainstream.

What people say Semax is a focus-related peptide with a Russian nasal-product history. People discuss clearer thinking and staying on task; healthy-user enhancement claims are largely anecdotal. Doses people talk about
Lower amounts discussed100–300 mcg intranasally per administration, commonly once or twice daily

Forum/clinic-chart reporting, not a recommended starting range.

Common cognitive charts250–600 mcg intranasally per administration, often once or twice daily

Plain Semax only; device output and concentration vary.

Plain Semax charts are not interchangeable with modified analogs, injectable products or clinical stroke regimens.

Half-life & effect duration

Half-life in the body
  • Secondary / community estimatesAbout 2–5 minutes or 15–20 minutes
Felt duration people report
  • Separate user accountsAbout 3 hours of noticeable effects, or most of the day
  • Longer community effect claimsAbout 20–24 hours
  • After-course reportsClarity for days, fading within 1–2 days, or 1–2 weeks in secondary accounts
  • Continued-use accountMild focus faded after a couple of weeks
Timing context & sources
How it may feel Accounts range from subtle clarity to no noticeable change. Nasal irritation, headache, anxiety and sleep disruption also appear, especially in mixed-nootropic logs.
Cycles people discuss People describe short work or study blocks, often around one to two weeks, with longer courses also discussed. Those schedules do not prove a receptor-reset rule or lasting gains. Timing Morning or earlier-day use dominates the discussion because later use is linked to sleep complaints. Combining it with caffeine or other nootropics makes the experience harder to attribute. Stacks + Selank (classic “focus + calm” pair): Semax for activating focus, Selank for anxiety/calm — often same course; some dose Semax AM and Selank midday/PM; some combine both in one nasal bottle (no published interaction data; targets framed as non-identical). Access talk How people actually talk about getting it: Imported Russian drops, gray-market research sprays, and reconstituted vials — identity and concentration are trust-the-label problems. Watch for Nasal irritation: Burning, dryness, congestion, sneezing, or runny nose — the most common complaint; worse with high frequency, harsh carriers, or poor technique.
Related
SelankAdamaxNoopeptDihexaP21

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

A human half-life is not established by the sources checked. The often-cited two-minute rat result is a sampling time, not an elimination half-life.

The research describes rapid breakdown and metabolites. It does not give a reliable human nasal or subcutaneous clearance number.

The original 2006 rat abstract was read. FDA's 2026 PK section, printed pages 34–35, describes rodent IV/IN studies and reports no identified subcutaneous PK study at that evaluation. Neither an absence across all possible literature nor equivalence of modified Semax products is claimed.

  • Shevchenko et al. (2006): nasal Semax distribution in rats (opens in a new tab)Original English abstract: labelled Semax in rat brain two minutes after intranasal administration, followed by rapid degradation and prominent Pro-Gly-Pro metabolite.Original abstract only; no numerical human elimination half-life. Sampling time and percentage of radioactivity are not a half-life.
  • FDA Semax briefing: pharmacokinetic context (opens in a new tab)Printed pages 34–35, Pharmacokinetics/Toxicokinetics and Figure 6: IV/IN rat studies, first two-minute collection and no identified subcutaneous PK study. Complete relevant pages visually inspected.Regulatory literature review, not a new human experiment or proof of current legal status. Underlying IV full study not independently read.

Felt duration people report

Two users describe about three hours of noticeable effects versus most of the day. Another reports that mild focus faded after a couple of weeks.

Those are individual experiences, not a proven duration range. Product, route and co-use can change what people notice.

Lev1sz and deathby_dumbbell do not specify route in the adopted passages; their disagreement cannot establish a dose-response rule. hlvnk initially combined Semax/Selank and later citicoline. The separate N-acetyl and stacked eight-hour accounts are not used for plain Semax.

What people say 21

  • Focus / attention: Sharper task focus, less mental drift; often described as “cleaner” than heavy caffeine or Adderall-class stims — more “on-task” than forced drive. forum
  • Working memory: Easier short-term hold of dense material during deep work or study blocks — largely anecdotal in healthy users. anecdote
  • Under stress / fatigue: Better mental performance on high-demand, exam, pilot/operator-style vigilance, or sleep-short days than baseline for some; Russian secondary literature cites preserved vigilance under cognitive load. forum
  • Mood: Mild calmer, less irritable baseline, or subtle antidepressant-like tone for a subset (animal stress/depression models + forum mood lift); others report pure cognition with neutral mood. forum
  • Vs stimulants: Less jitter, appetite crash, and comedown than amphetamine-class; also often less raw motivation push — non-responders call it subtle-to-nothing. forum
  • Stack confounding: Very often co-logged with Selank, N-Acetyl variants, racetams, Noopept, caffeine, or prescription stims — single-agent credit is unreliable. forum
  • Null / subtle responders: A sizable minority report “nothing” or only sensory alertness for ~15 min then fade — product quality, technique, expectation, and sleep are the usual debates. forum
  • Brain fog / word-finding (community): Responders describe less fog and easier word access during a work block; a large minority still report “nothing but a sting.” forum
  • Stroke / rehab (human clinical): Gusev et al. 2018 rehab series (n=110 post-ischemic stroke): two courses of 6000 mcg/day × 10 days with ~20-day interval; plasma BDNF rose and stayed elevated; motor performance (BMRC) and Barthel improved, with early rehab + Semax framed as additive. trial
  • Acute stroke product/historical doses: Russian 1% product literature and older series discuss multi-mg daily totals (e.g. mild–moderate ~6–12 mg/day class; severe ~12–20 mg/day class over ~5–10 days) under clinical supervision — not healthy nootropic dosing. Some secondary sources simplify acute stroke to ~12–18 mg/day. trial
  • BDNF (human clinical context): Plasma BDNF increases reported alongside functional scores in stroke-rehab Semax arms — does not prove healthy-enhancement benefit or optimal nootropic dose. trial
  • BDNF/NGF (rodent): Hippocampal and cortical Bdnf/Ngf mRNA and protein changes after nasal or systemic doses; learning endpoints improve in some models; gene-expression waves reported within hours of a dose. animal
  • Nasal > systemic (rats): Manchenko et al. and related work: intranasal often beats intraperitoneal on learning/CNS endpoints; secondary literature cites better relative brain exposure vs tiny BBB fraction after IV. animal
  • fMRI / network talk: Small healthy-volunteer fMRI work (e.g. default-mode-network changes within minutes after 1% nasal) is cited in secondary reviews — mechanistic interest, not an enhancement trial. trial
  • Optic nerve / visual pathway: Russian product history and method literature discuss 0.1% instillations for optic-nerve disease contexts (e.g. ~600–900 mcg/day class over ~7–10 days in secondary label reproductions) — not a Western nootropic use case. trial
  • Glaucoma adjunct series: Small safety/efficacy glaucoma work over ~1 month with no major adverse events reported in secondary summaries — still clinical, not DIY. trial
  • Peptic ulcer (product history): Clinical series reported faster ulcer healing when Semax was added to standard ulcer therapy (e.g. high healing rates vs basic therapy alone in older Russian work) — fringe to nootropic forums. trial
  • Antiplatelet / ischemia adjunct talk: Secondary Russian work links chronic ischemic-brain-disease benefits partly to neurotrophic plus antiplatelet properties — mechanism lore, not a blood-thinner substitute. trial
  • Immune / neutrophil talk: Lab work on neutrophil respiratory burst with Semax is recycled in product pages as “immune support”; minor in Western focus threads. lab
  • Alcohol delirium / cognitive recovery (product history): Small series in alcohol delirium reported reduced asthenic/autonomic symptoms and better cognitive recovery framing — historical clinical context, not a party nootropic. trial
  • Non-hormonal ACTH framing: Product and review literature stress lack of steroidogenic ACTH/MC2 activity at nootropic/neuroprotective doses — core marketing differentiator from full ACTH. trial

Doses people talk about 22

  • Nasal charts: Common discussion: hundreds of mcg per administration, 1–2× daily during short courses (exam/sprint blocks). forum
  • Beginner / light nasal nootropic: ~100–300 mcg per administration, 1–2× daily — common first band in clinic blogs and forums for tolerance and “is anything happening?” checks. forum
  • Standard community cognitive band: ~250–600 mcg per dose, 1–2× daily (often morning ± early afternoon); many guides call ~300–600 mcg 1–3× daily the modal nootropic schedule. forum
  • Parahealth-style research schedules (community/vendor synthesis): (1) Standard cognitive: 250–500 mcg once daily morning; (2) Twice-daily split: 250–500 mcg AM + 250–500 mcg early afternoon; (3) High-stress acute load: 500–1000 mcg once, ~60–90 min before a demanding task; (4) Stroke-context research high end discussed separately. forum
  • Broader per-dose band: ~250–1000 mcg nasal per administration appears across Russian-style summaries and research-chem charts depending on goal and strength. forum
  • Total daily nootropic (typical talk): Roughly ~300–1500+ mcg/day split; upper end approaches light clinical cognitive-disorder schedules (~600–900 mcg/day for ~14 days in some secondary cognitive-disorder summaries). forum
  • Peptides.org-style nasal research chart: The chart describes beginning around ~600–900 mcg/day, often framed as 2–3 pumps when each pump is assumed to deliver ~300 mcg, and changing amounts by response. It also describes courses up to ~30 days, alternate ~600 mcg/day discussion up to ~60 days, and washout approximately equal to time on. These are reported chart practices, not an instruction or a verified output for every pump. forum
  • High-stress acute load (community/research charts): ~500–1000 mcg once, ~60–90 min (sometimes 30–45 min) before a demanding task — acute rather than chronic pattern. forum
  • SubQ minority charts: Wide scatter — some research-chem guides ~100–500 mcg/day SC or ~400 mcg/day; peptides.org-style samples ~500 mcg–1 mg SC once daily for ~4–8 weeks; some clinic-style logs ~400 mcg/day 4 days/week × 4 weeks on/4 off; Perfect B-style injectable charts discuss ~0.5 mg (weeks 1–2) then ~0.8 mg (weeks 3–8) once daily, 5 days on / 2 off, then long rest — these do not map cleanly to nasal clinical history and should not be treated as equivalent. forum
  • N-Acetyl / NASA: Separate lower-mcg culture for dual-capped analogs (often ~200–400 mcg NASA vs ~300–600 mcg plain as modal bands; some blogs claim ~30–40% lower mass equivalence) — do not copy plain-Semax mcg charts onto N-Acetyl Semax Amidate or vice versa. forum
  • Timing rule: Morning and early afternoon preferred; typical split ~7–9 AM and ~11 AM–1 PM, optional third ~2–4 PM; last dose often capped by midday/early afternoon (~by 4 PM in many guides) to protect sleep. forum
  • Empty-stomach talk: Some research guides prefer morning dose “on empty stomach” for cognitive protocols — not a hard PK requirement for nasal absorption (food does not affect nasal uptake in community writeups). forum
  • Titration habit: Forum guides describe beginning at the lower end for 2–3 days for nasal tolerability, then changing amounts according to subjective focus and sides. This is reported practice, not a recommended adjustment rule; the existing Russian-clinical-use discussion describes no published loading-dose phase. forum
  • 2026 nasal vs SubQ camps: Nasal remains the Russian-studied and dominant nootropic route (hundreds of mcg, 1–3×/day). The SubQ camp argues once-daily consistency and higher systemic exposure; research-chem charts often sit ~300–600 mcg SC once daily (some vendor charts higher). Those mcg are not 1:1 swaps — nasal is a CNS bet, SubQ is a different PK story. forum
  • Nasal-bioavailability lore: 2025–2026 vendor/forum tables often quote ~60–70% nasal bioavailability for Semax. That number circulates as class lore, not a published Western human PK table. forum
  • Math risk: Drop volume × % concentration errors, unknown spray pump output (often assumed 0.1 mL), and mislabeled research sprays make stated mcg shaky without verified concentration and device output. Confusing 0.1% with 1% is a serious overdose risk. forum
  • 1% / stroke-range product talk: Much higher mcg per drop (~500 mcg/drop class in secondary sources); mild–moderate stroke often reproduced as ~2000–3000 mcg per administration × 3–4/day (~6–12 mg/day) for ~10 days; severe stroke ~3000–4000 mcg × 4–6/day at shorter intervals (~12–20 mg/day class) for up to ~10 days — clinical supervision context only. trial
  • Gusev rehab regimen (published): 6000 mcg/day for 10 days × 2 courses with ~20-day interval between courses in post-ischemic-stroke rehab study. trial
  • Acute stroke multi-mg shorthand: Secondary clinical writeups often cite ~12 mg/day moderate and ~18 mg/day severe over 5–10 day courses in older acute hemispheric-stroke series — still not nootropic dosing. trial
  • Weight-based note: Adult Russian product talk is mostly fixed adult doses; pediatric/stroke contexts sometimes use weight-based language — nootropic community almost never weight-adjusts. trial
  • Framing: Discussed research, Russian product-label reproductions, and community ranges only — not medical advice, prescriptions, or validated Western protocols. Concentrations and drop/spray calibration make “mcg” claims product-specific. forum
  • 0.1% Russian label-style bands (secondary reproductions of Vidal/product inserts — not a U.S. label): Mental exhaustion ~400–900 mcg/day split 2–3× for ~3–5 days; optic-nerve ~600–900 mcg/day split 2–3× for ~7–10 days; cerebrovascular/encephalopathy-class single applications ~200–2000 mcg (sometimes framed ~3–30 mcg/kg) up to ~4× daily for ~10–14 days (daily totals spanning roughly ~800–8000 mcg depending on severity language); pediatric mild-cognitive product talk historically ~200–400 mcg/day split × ~30 days under clinical care — not a self-experiment template. trial

How it may feel 10

  • Minutes 10–30: Common subjective nasal onset window in forums — mild alertness, sensory “on,” cleaner verbal fluency, or no change; some feel almost trippy/odd on first exposures. Secondary sources often quote ~15–20 or ~15–30 min. forum
  • Minutes 20–60: Peak “is this working?” check for many; nasal sting and post-nasal drip often precede any cognitive claim. forum
  • Hours 1–6: Focus window often claimed for a working block; downstream neurotrophin talk used to justify effects lasting longer than plasma life. Forum “2–4 hour feel” is functional, not serum PK. forum
  • Day 1: Mild focus edge, nasal irritation, mild wired feel, or flat response; late-day dosing may show sleep cost that night even when “stim feel” is gone. forum
  • Days 1–3: Tolerance check for nasal burn, headache, restlessness, anxiety flip, and sleep; many decide if the edge is real vs placebo. forum
  • Days 3–5 / 5–14: Typical “exam or deep-work block” checkpoint for attention, productivity, and mental stamina claims; some guides frame cumulative BDNF/gene-expression style build mid-course rather than caffeine-like day-1 fireworks. forum
  • Weeks 2–4: Some claim steadier mental stamina across a course; others plateau, blunt, get irritable/fatigued, or stop when demand ends. forum
  • After course: Residual clarity days for some; rapid fade within 1–2 days for others; secondary writeups sometimes say BDNF-style residual declines over ~1–2 weeks — permanent gains are not established. anecdote
  • Anxiety vs stimulation split: The same nasal course can read as clean focus or as edgy/anxious — more often with caffeine, higher mcg, or late timing. forum
  • Sleep cost: Evening or late-afternoon sprays are a recurring insomnia story even after the “stim feel” is gone. forum

Around the dose 4

  • Clock: Morning / early afternoon nasal; many logs cap the last spray by ~2–4 PM. Evening Semax is a common insomnia complaint. forum
  • Work block: People take it then actually do the deep-work or study block — it’s framed as an on-switch, not a night peptide. forum
  • Dihexa stack warning: Same-weeks high Semax + high Dihexa appears in community “too loud” warnings; multi-agent accounts cannot isolate attribution. forum
  • Caffeine: Extra coffee on Semax days is a common overstim / headache story. forum

Cycles people discuss 13

  • Short work blocks: 5–14 day runs for exams, sprints, or high-demand periods — most common Western community pattern. forum
  • Nootropic cycle default: ~7–14 days on, then break of equal or greater length (e.g. 2 weeks on / 2 weeks off) is a common conservative framework; variants include 5 on / 2 off micro-cycles or 14 on / 7 off. forum
  • Longer calculator charts: Up to ~30 days at higher daily totals, or ~60 days at moderate ~600 mcg/day-class totals with washout ≈ on-time in some research-chem guides. forum
  • Pulse vs continuous: Pulsed on load weeks more common than open-ended multi-month daily; continuous months logged less often and lack long-term healthy-adult safety tables. forum
  • Time off: Days to several weeks between blocks to reassess sleep, nasal mucosa, hair/skin changes, and whether benefit returns. forum
  • Injectable cycle talk (minority): Some SC charts run longer (e.g. ~4–8 or up to ~12 weeks with days-on/days-off, or 5/2 weekly patterns for ~8 weeks then multi-month rest) than typical nasal 10–30 day courses — vendor protocol culture, not Russian pharmacy standard. forum
  • Loading / taper: No published loading phase; Russian clinical use starts at target course dose. Taper generally not claimed as necessary (no classic withdrawal lore). forum
  • Re-runs: Restart for later demand spikes or scheduled Russian-product “courses per year” talk; cumulative long-term risk tables for healthy users not established. forum
  • With Selank: Often same calendar (both on for a course) rather than staggered cycles; some dose Semax AM and Selank midday/PM. forum
  • Cycling rationale honesty: Clear tolerance/downregulation pattern is not well characterized; cycling is largely precautionary / racetam-culture habit plus nasal-mucosa rest, not a proven receptor-reset rule. forum
  • Course culture: Often ~10–20 day runs then off — mirrors older Russian peptide course patterns in English forums. forum
  • Stroke / acute neuro courses: Multi-day to ~5–14 day high-strength courses in product literature; rehab studies use repeated 10-day blocks with multi-week gaps (e.g. 10 on / ~20 off / 10 on). trial
  • Russian-style cognitive courses: Often ~7–14 or ~10–30 day nasal courses in product and secondary clinical summaries (0.1% cognition/asthenia framing); mental-exhaustion product language can be as short as ~3–5 days. trial

Timing 12

  • Parent half-life and secondary estimates: Secondary PK summaries circulate ~2–5 minutes, while some community writeups say “15–20 minutes plasma.” Neither is established here as measured human clearance. The original intranasal rat study’s two-minute value is a sampling time, not an elimination half-life; it describes rapid degradation rather than a long circulating depot. animalforum
  • Downstream / “effect half-life” talk: Older discussions describe therapeutic or functional effects lasting many hours to ~20–24 h after a dose, attributing this to BDNF/NGF transcription, monoamine shifts, enkephalinase effects and fragment activity rather than blood levels alone. These are downstream-effect claims and proposed mechanisms, not a measured human clearance value or an established duration for every user. animalforum
  • Multi-dose daily discussion: Community charts describe 1–3× daily nasal use to maintain a daytime cognitive window and invoke short-plasma-life lore rather than weekly-depot logic. Those schedules are reported practice, not intervals established by measured human Semax clearance. forum
  • Onset: Subjective nasal onset commonly minutes to under an hour (~15–20 or ~20–40 min often claimed). forum
  • Feel window: Multi-hour focus commonly claimed; “2–4 hour feel” in forums usually means downstream signaling, not plasma persistence. forum
  • Daytime-only bias: Alertness and insomnia reports lead community schedules to place the last dose in the first half of the day. Sleep complaints can outlast the acute alert feeling; these reports do not establish when the peptide has left human plasma. forum
  • Oral: Negligible oral bioavailability assumed — gastric/intestinal peptidases destroy the chain; oral Semax is not a serious community route. forum
  • Route hierarchy: Nasal preferred for nootropic/CNS goals and matches clinical history; subQ is minority Western research-chem practice (more consistent systemic exposure claims, less nose-to-brain lore); IP is animal-only. forum
  • PGP metabolite: Parent metabolized to Pro-Gly-Pro, itself framed as biologically active with longer tissue residence than the heptapeptide — one explanation for effect outlasting blood levels. animal
  • BDNF gene timing (preclinical): Bdnf/Ngf transcription changes reported within ~30–90 min after exposure; expression can return toward baseline over hours (e.g. toward ~8 h in some temporal studies); other occlusion models show staggered neurotrophin/Trk gene waves at ~3 h, 24 h, and 72 h. animal
  • CSF / brain exposure (preclinical talk): Secondary literature cites CSF concentrations rising within ~30 min of intranasal dose and reaching a large fraction of plasma levels in rodents (sometimes “~60–70% of plasma” class claims) — supports nasal preference, not a human AUC table. animal
  • Nasal vs IV/IP BBB (preclinical): Secondary literature and Manchenko-type comparisons cite higher relative brain penetration or learning potency after intranasal versus systemic routes within minutes in animal work. These comparisons do not establish a preferred human route or route-equivalent amounts. animal

More on what it is 11

  • Why people use it: One of the highest-volume cognitive peptides in biohacking — Russian Rx nasal drug history (0.1% and 1% drops on vital/essential drug lists historically) plus “clean focus” forum lore without classic stimulant jitter or amphetamine comedown. forum
  • Not the same as: FDA-approved drug; amphetamine/modafinil-class stims; Selank (tuftsin-derived calm peptide); plain N-Acetyl Semax (single N-cap); N-Acetyl Semax Amidate / NASA (dual-capped); Adamax (adamantyl/related “stronger Semax” community variant). Dose cultures differ. forum
  • Purity caveat: Imported Russian pharmacy multi-dose drops ≠ research-chem lyophilized powder or DIY sprays. Concentration, identity, fill volume, and preservative quality are trust-the-label problems on gray markets. forum
  • 2026 size/route talk: Semax is a small heptapeptide (~813 Da) that 2025–2026 absorption charts put under the ~1 kDa “nasal can work” lore cutoff. Forums treat Semax/Selank as *designed* for nose-to-brain (olfactory/trigeminal), not as a BPC- or GLP-1-style spray. forum
  • Bro/nootropic framing: Nasal “focus peptide” from Russian nootropic culture — courses, not endless daily forever for many users. forum
  • What it is: Synthetic 7-amino-acid peptide MEHFPGP (Met-Glu-His-Phe-Pro-Gly-Pro) — ACTH(4-7) melanocortin core extended with a Pro-Gly-Pro C-terminal tail for peptidase resistance; developed at the Institute of Molecular Genetics (Russian Academy of Sciences; Ashmarin / Myasoedov-era work; first described ~1991). Approximate MW 813.93 Da; formula C37H51N9O10S. trial
  • Mechanism talk (forum compression): Rapid BDNF and NGF upregulation with TrkB signaling in hippocampus/cortex; monoamine (dopamine/serotonin) turnover shifts; enkephalinase inhibition (IC50 classically cited ~10 μM with Selank); melanocortin engagement (reports of competitive antagonism/partial-agonist behavior at MC4/MC5 vs α-MSH; MC3 less clear); anti-ischemia / anti-apoptotic / anti-inflammatory gene programs in stroke models. Exact human mechanism still incomplete in secondary reviews. animal
  • PGP tail rationale: Unmodified ACTH(4-7) is cleaved in seconds; Pro-Gly-Pro slows carboxypeptidase attack and yields an active PGP fragment that secondary sources say can accumulate in brain with longer residence than the parent heptapeptide. animal
  • Evidence honesty: Russian stroke/rehab, optic-nerve, cognitive-disorder, and product-label history denser than Western RCTs for healthy-adult enhancement. Gusev et al. and related series are the usual human anchors; gray-market Western use is mostly anecdote + vendor charts. No FDA/EMA approval for cognition or any U.S. indication. trial
  • Regulatory: Registered Eastern European / Russian pharmaceutical with stroke, TIA, memory/cognitive disorders, peptic ulcer, optic-nerve, and immune-boost product-talk indications historically; U.S. unscheduled/not FDA-approved; sold as research chemical online. ATC class discussions sometimes list N06BX. trial
  • July 2026 PCAC: FDA’s Pharmacy Compounding Advisory Committee recommended Semax (free base and acetate) for the 503A bulks list — reported tally about 8–5 with one abstention — for nominated uses including cerebral ischemia, migraine, and trigeminal neuralgia. Advisory only: not an FDA approval, not a listing yet, and agency staff had recommended against all seven peptides that week. trial

Stacks 14

  • + Selank (classic “focus + calm” pair): Semax for activating focus, Selank for anxiety/calm — often same course; some dose Semax AM and Selank midday/PM; some combine both in one nasal bottle (no published interaction data; targets framed as non-identical). forum
  • + N-Acetyl Selank Amidate: Same dual-stack idea with the capped Selank analog; common Western research-chem pairing with NASA or plain Semax. forum
  • N-Acetyl Semax or NASA swap discussion: Users describe alternating or replacing plain Semax when they prefer longer perceived duration or lower mcg. These are different molecules and dose cultures; dual-cap lore often describes 1–2× daily versus 2–3× for plain Semax, not a verified equivalence or substitution rule. forum
  • + Adamax (related talk): Stronger/more stim “Semax-family” variant in some communities; not interchangeable 1:1 with plain Semax. forum
  • + Racetams: Piracetam, phenylpiracetam, or related in older nootropic-forum stacks. forum
  • + Noopept: Frequent co-mention in cognitive peptide stacks; multi-agent logs confounded. forum
  • + Dihexa / P21: Occasional “neuroplasticity stack” co-logs on research forums — sparse controlled data; attribution messy. anecdote
  • + Caffeine / L-theanine: Very common layer; watch overstimulation, especially with higher Semax or NASA. forum
  • + Prescription stimulants (ADHD meds): Discussed for “potentiation” and edge — also higher anxiety/insomnia risk; medical supervision territory, not a validated combo. forum
  • Exercise same day: Some note exercise also raises BDNF and may feel additive at the lifestyle level — not a proven synergy trial. forum
  • Mitochondrial / recovery peptides: Occasional co-logs with BPC-157/TB-500 or mito stacks in biohacker polypharmacy — attribution messy. anecdote
  • Solo-first attribution habit: Community notes describe using Semax alone for a few days before stacking so nasal sides, sleep and hair/skin changes are easier to attribute. This is a reported habit, not a recommended introduction schedule. forum
  • Sleep / timing hygiene: Earlier dosing plus sleep protection often credited as much as the stack math for good outcomes. forum
  • Combo spray bottles: Some Western vendors/telehealth charts put Semax + Selank in one nasal bottle — two peptides, messier mcg math and attribution. forum

Access talk 4

  • How people actually talk about getting it: Imported Russian drops, gray-market research sprays, and reconstituted vials — identity and concentration are trust-the-label problems. forum
  • Not Selank: Selank was not on that July seven-peptide panel. Do not copy Semax compounding headlines onto Selank. forum
  • Russian pharmacy drops: 0.1% and 1% nasal products are the labeled clinical history — not a U.S. approved drug. trial
  • July 2026 PCAC: Committee recommended Semax (free base/acetate) for the 503A bulks list (reported ~8–5–1). The vote is advisory; nothing is automatically legal to compound until FDA rulemaking. trial

Storage notes 2

  • No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
  • Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Watch for 18

  • Nasal irritation: Burning, dryness, congestion, sneezing, or runny nose — the most common complaint; worse with high frequency, harsh carriers, or poor technique. forum
  • Headache: Mild headaches in a notable minority; dose, dehydration, or stack stims often blamed; late-day headaches appear in some short trial logs. forum
  • Insomnia / delayed sleep: Late dosing can wreck sleep even when “stim feel” is mild; morning/early-day preferred; dopaminergic activation talk is the usual forum explanation. forum
  • Anxiety / restlessness / edginess: More common at higher doses, with caffeine/stims, or in anxiety-prone users; opposite of the “clean calm focus” marketing. forum
  • Fatigue or emotional blunting: Occasional after multi-week daily use or in odd responders. anecdote
  • Taste / sensory: Metallic taste, brief nasal pressure, post-nasal drip, or short “senses turned up” window then flat. forum
  • Hair loss / shedding (major community caution): Recurring r/Nootropics reports of accelerated shedding while on Semax; mechanism lore ties BDNF elevation to hair-cycle disruption. Some report regrowth weeks–months after stopping; others claim lasting thinning — causality unproven but widely discussed enough that “Semax hair loss” is a standard search. anecdote
  • Vision anecdotes: Rare long-term nasal-user stories of visual change (e.g. needing glasses) appear on forums — causal link unproven; still a caution flag people mention alongside high-frequency nasal use. anecdote
  • Overstimulation stacks: Semax + strong stimulants or high NASA doses can feel wired without productive focus. forum
  • Overdose / mega-dose lore: Forum megadose mistakes exist; clinical stroke totals reach multi-mg/day without classic acute toxicity signals in product literature, but nootropic overshoot still commonly means headache, insomnia, or fatigue rather than a license to dose carelessly. forum
  • Purity / mislabel risk: Wrong concentration, underfilled sprays, degraded peptide, or contamination on gray markets; pharmacy Russian product ≠ research vial. forum
  • Concentration mix-ups: Confusing 0.1% cognitive drops with 1% stroke-strength product is a serious dosing error risk (order-of-magnitude mcg difference per drop). forum
  • Not risk-free: Claims of short plasma half-life do not mean zero CNS, mucosal, or hair-cycle risk; long-term continuous Western data remain limited. forum
  • Regulatory / legal: Russia/Ukraine Rx status ≠ FDA approval or legal consumer use everywhere; research-only framing in most Western jurisdictions. forum
  • Evidence gap: Stroke and Russian clinical literature do not prove healthy-adult enhancement, optimal nootropic dose, or long-term safety of gray-market daily use. trial
  • Special populations: Pregnancy, pediatrics (Russian product has pediatric MCD talk historically under clinical care), serious neuro disease, active ulcer treatment contexts — clinical contexts, not self-experiment templates. trial
  • PCAC ≠ green light: The July 2026 yes-vote is a committee recommendation sitting in rulemaking. Compounding status can change and is not “FDA cleared Semax.” Staff briefing language flagged characterization gaps and possible anti-thrombotic properties. trial
  • Russian clinical safety framing: Multiple clinical series (glaucoma, fMRI volunteers, stroke adjunct) report no major adverse events at studied regimens in secondary summaries — does not prove long-term healthy gray-market safety. trial

Updated: 2026-09-01

Evidence mix Mostly community / anecdote tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.
↑ Back to top

All STUDresearch topics →